.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,676,946

« Back to Dashboard

Details for Patent: 6,676,946

Title: Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
Abstract:A carbohydrate peptide conjugate containing: (i) a carrier containing a dendrimeric poly-lysine enabling multiple epitopes to be covalently attached thereto, (ii) at least one peptide containing one T epitope or several identical or different T-epitopes, (iii) at least one carbohydrate moiety which is tumor antigen, or a derivative thereof, containing a B epitope, provided it is not a sialoside, or several identical or different epitopes, wherein said conjugate containing at least 3-lysines and up to 15 lysine covalently linked to one another, and wherein: (a) to the NH.sub.2 and of at least two lysine residues is bound at least one carbohydrate residue being not a sialoside, optionally substituted and containing an epitope and wherein the peptide containing one T epitope is covalently bound to the end of said carbohydrate which induces immune responses.
Inventor(s): Bay; Sylvie (Paris, FR), Cantacuzene; Daniele (Paris, FR), Leclerc; Claude (Paris, FR), Lo-Man; Richard (Paris, FR), Vicher-Guerre; Sophie (La Celle Saint Cloud, FR)
Assignee: Institut Pasteur (FR)
Filing Date:Sep 27, 1999
Application Number:09/405,986
Claims:1. A carbohydrate peptide conjugate selected from the group consisting of the conjugates of the following formulae (a) to (f): ##STR2##

wherein: K is a lysyl residue, T is a CD4 T.sup.+ cell peptide epitope; B and Tn is a Tn antigen selected from the group consiting of .alpha.-Gal-Nac, .alpha.-Gal-Nac-Ser, .alpha.-Gal-Nac-Thr, .beta.-Gal-Nac, .beta.-Gal-Nac-Ser, .beta.-Gal-Nac-Thr, .beta.-Gal-(1-3)-.alpha.-Gal-Nac-Ser, .beta.-Gal(1-3).alpha.-Gal-Nac-Thr(.alpha.-Gal-Nac-Ser/Thr).sub.2, (.alpha.-Gal-Nac-Ser/Thr).sub.3 and (.alpha.-Gal-Nac-Ser/Thr).sub.6.

2. A immunogenic composition comprising the conjugate of claim 1 and a suitable carrier.

3. A immunogenic composition the conjugate of claim 1 and a suitable carrier and adjuvant.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc